Tubulis

Science & Engineering · Biotechnology

Facts

as of Nov 17, 2026

Tubulis is now part of Gilead Sciences. Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026.

Legal name
Tubulis GmbH
Founded
2015
Employees
501-1000estimated range
Register numbers
VAT DE325089835
Official records
Wikidata Q140045596
Website
tubulis.com

These are the key facts about Tubulis on Alion as of Nov 17, 2026. It was founded in 2015. It has raised $564M in 3 funding rounds. The latest round is Series C of $361M, announced in 2025.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Tubulis GmbH
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$564MTotal raised
$1.1MPublic grants4 public grants
GrantLatest round
7Rounds and grants
Money by yearUSD, rounds and grants
2026$501k1 record
2025$361.3M2 records
2024$138.2M1 record
2022$64.8M1 record
2021$149k1 record
2020$194k1 record
Largest rounds and grants
$361M
$64.8M
2026
$501k
2025
$294k
Sources: funding announcements, grant and company registers

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

Apr 212026
News · YahooFinance
MUNICH, April 21, 2026--Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been acce…
Apr 72026
News · MedCity News
Gilead Sciences' Tubulis acquisition brings antibody drug conjugates in clinical development for cancer. Analysts say the Tubulis platform technologies that yielded these ADCs co…
Jan 212026
News · YahooFinance
MUNICH, January 21, 2026--Tubulis today announced the publication of preclinical proof-of-concept data for its novel Alco5 conjugation platform in Nature Communications. The pape…
Oct 15, 20252025
News · Pulse 2.0
Tubulis announced the closing of a €308 million ($361 million) Series C financing round aimed at accelerating the clinical development of its lead antibody-drug conjugate (ADC) c…
Oct 15, 20252025
News · STAT
The company, which is developing antibody-drug conjugates, will use the funding to push its lead drug candidate into trials in additional types of cancer.
Oct 15, 20252025
News · YahooFinance
The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer drug that's currently in early-stage testing.
Sources: the outlets named on each headline, each story once